Cedric Francois, Apellis CEO (Apellis)
Apellis' Soliris rival gets a date at the FDA for a rare blood disorder, with potentially $400M worth of implications
Apellis $APLS is one step closer to catching its rival for the rare blood disorder PNH.
The Waltham, MA-based biotech announced that the FDA has …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
